Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty

摘要

Background: Triptorelin is an established treatment for central precocious puberty (CPP) as 1- and 3-month formulations. The current triptorelin 22.5 mg 6-month formulation is approved for prostate cancer therapy. This is the first study in patients with CPP.